NCT05316129View on ClinicalTrials.gov

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

May 31, 2029

Conditions

Ovarian Cancer

Interventions

DRUG

Follicle Stimulating Hormone Receptor T Cells

Participants will receive an infusion of autologous t cells genetically modified ex vivo to express the FSHR-specific 4-1BB/CD3ζ CER.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

Anixa Biosciences, Inc.

All Listed Sponsors

collaborator

Anixa Biosciences, Inc.

UNKNOWN

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER